Pioneering technology

Xerion’s technology improves the effectiveness of conventional radiotherapy while minimising side-effects. The company’s Oxilia nanoparticles have a physical mode of action and offer the ability to improve treatment of a wide range of solid tumours.

A strong background, a strong future

Spun out from Oxford University in 2015 following eight years of research, Xerion Healthcare is based and founded in the UK to develop and commercialise Oxilia treatment.

Best-in-class nanomedicine

  • Oxilia has a physical mode of action and Best-in-class radio sensitiser delivering unparalleled dose enhancement of radiotherapy
  • Targeting a wide range of poorly treated solid tumours – initial focus on head & neck cancer
  • Regulated as a class III medical device

Strong IP position

  • Granted patents: EU, US, China, Japan
  • Patent protection to 2037
  • Clear freedom-to-operate position
  • Extensive manufacturing know-how

The Xerion Team

Xerion’s management team has extensive commercial experience combined with pioneering nanotechnology expertise and support from world-leading oncologists.

Justin Stebbing

Prof Justin Stebbing, Chairman

Professor of Life Sciences at ARU, Cambridge

Read more
Ian George

Ian George, NED

Tech investor, extensive experience in developing & raising funds for healthcare companies

Read more
Gareth Wakefield

Gareth Wakefield, CEO

Co-founded Oxonica, over 20 years experience in materials & nano-technology start-ups

Read more
Megan Adiar

Megan Adair, Quality and Operations Manager

Over 10 years experience in quality assurance and quality control

Read more
Read about us in the press

Company Timeline


Xerion is founded to bring Oxilia to market, based on patent filed in 2010

Xerion files patent to expand the scope of technology and its applications

August 2015 - Seed investment from New Wave Ventures & Parkwalk Advisors


Innovate UK Biomedical Catalyst early stage grant awarded

Xerion’s technology efficacy and safety demonstrated in vivo

December 2017 - Investment from Oxford Sciences Innovation


Innovate UK Biomedical catalyst feasibility grant awarded

April 2018 - Prof Justin Stebbing appointed to company Chair


September - Innovate UK Biomedical Catalyst late stage grant awarded to support product scale-up & pre-clinical testing

X Icon